Additionally, Syk inhibitors downregulated inflammation (cytokine production and extracellular traps) in macrophages and neutrophils (more prominently in FcγRIIb−/− cells than WT cells) in the Syk-p38MAPK-dependent pathway and were proposed as an interesting candidate for the treatment of active lupus, especially in patients with FcγRIIb dysfunction polymorphism. This evidence concerns the gene FCGR2B and systemic lupus erythematosus.